Serological prevalence of human parvovirus B19 in diseases or disordersrelated to different human body systems

Abstract

IntroductionHuman parvovirus B19 (B19), frequently seen all over the world, is a pathogenic agent associated with various diseases and disorders that affect different body systems. Erythema infectiosum, chronic arthritis, spontaneous abortion, hematological disorders, myocarditis, and glomerulonephritis are only some of these (1-3). B19 is spread from person to person by infected respiratory secretions, by infected blood and blood-product transfusions, and by vertical transmission from mother to fetus (4,5).B19-specific IgM antibodies appear 10-12 days after exposure to the virus and may be detected in serum for 3-6 months. IgG antibodies appear after approximately 2 weeks and persist for life (6). The prevalence of antibodies to B19 has been reported at higher rates in studies carried out in different geographic regions. Approximately 15% of preschool children, 50% of adults, and 85% of the elderly Background/aim: Human parvovirus B19 is a pathogen that affects different parts of the body. We planned this study because of the lack of data on B19 seroprevalence based on different body-system diseases. Materials and methods:The prevalence of parvovirus B19 antibodies was investigated retrospectively in 1239 patients by review of medical records from 2009-2012, according to their diseases classified under general titles in compliance with the International Classification of Diseases (ICD-10). Parvovirus B19-specific antibodies were detected by quantitative enzyme immunoassays. Results:The positivity rate was 27.8% for only IgG, 8.5% for only IgM, and 2.6% for both IgG and IgM. The highest positivity for IgG alone was found in musculoskeletal system and connective tissue diseases (55.9%), while the highest positivity for IgM was found in neoplasms (16.4%). The highest positivity for IgG was seen in rheumatoid arthritis (72.2%) and pregnancy (52.6%), and the highest positivity for total IgM was found in upper respiratory tract disease (21.0%) and hepatic failure (17.1%).Conclusions: Parvovirus B19 seroprevalence was relatively low in northeastern Anatolia compared to most serological studies conducted in other regions. We think that this study has provided the first wide-ranging information on the seroprevalence of B19 in diseases and disorders of the major human body systems.

Investigation of Parvovirus B19 Antibodies in Serum Samples with Pre-diagnosis of Arthritis-Arthralgia

“…[27] In Erzurum, Aktas et al found in the general population that parvovirus IgG was 27.8%, IgM was 8.5% and IgM and IgG seropositivity together was 2.5%. [28] In Ankara, Goral et al found in blood donors that parvovirus B19 IgG seropositivity was 58.9% and IgM seropositivity was 3.92%. [29] In this study, parvovirus B19 IgG positivity was 66% and IgM positivity was 3% in patients with prediagnosis of arthritis/arthralgia.…”

“…Low rates of IgM seropositivity were consistent with the ones in other similar studies. [28,29] Parvovirus B19 IgM prevalence in the general population is generally under 2%. However, the rate may be higher, depending on the duration of the outbreak cycle.…”

Investigation of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard to age groups and comparison with literature

“…Parvovirus B19 özgül Ig M antikorları virüse maruz kalınmasından yaklaşık 10 gün sonra ortaya çıkar ve 3-6 ay kalabilir, Ig G antikorları ise yaklaşık 2 hafta sonra ortaya çıkar ve ömür boyu kalır. Bu antikorların prevalansı bölgeden bölgeye değişebilir [12].…”

“…Ülkemizden konuyla ilgili farklı hasta grupları ve farklı yaş gruplarını içeren çalışmalar bulunmaktadır. Ülkemiz çalışmalarına bakıldığında farklı hasta ve yaş grubundaki çalışmalardaki oranlar %16-64 arasında değiştiği görülmektedir [2,[11][12][13][14][15]. Parvovirus B19 prevalansı ile ilgili ülkemizden farklı hasta grupları ile yapılmış çalışmaların sonuçları Tablo 2' de yer almaktadır.…”

“…[15] 2013 Sistemic lupus eritematozus 50 64 Aktaş ve ark. [12] 2016 Tüm hasta grupları 1239 27,8 Aktaş ve ark. [12] 2016 Gebe ve çocuklarda 19 52,6 Mevcut çalışma 2017 Gebeler 156 64,7…”